Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First in Human Phase I Study of 225Actinium-MTI-201 (225Ac-MTI-201) in Metastatic Uveal Melanoma

NCT05496686 is registered in ClinicalTrials.gov with Modulation Therapeutics, Inc. as lead sponsor.

NCT NCT05496686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05496686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First in Human Phase I Study of 225Actinium-MTI-201 (225Ac-MTI-201) in Metastatic Uveal Melanoma
Lead sponsor
Modulation Therapeutics, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 21, 2022
Completion date
February 25, 2029
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic, uveal melanoma